Generated by All in One SEO v4.9.8, this is an llms.txt file, used by LLMs to index the site.

# InSyBio

Intelligence Systems Biology

## Sitemaps

- [XML Sitemap](https://insybio.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [New Scientific Publication on TRAF3 in Breast Cancer Cell Survival and Immune Regulation](https://insybio.com/new-scientific-publication-on-traf3-in-breast-cancer-cell-survival-and-immune-regulation/) - InSyBio is happy to announce a new scientific publication titled “Dual Role of Cancer Epithelial-Specific TRAF3 in Regulating Breast Cancer Cell Survival and Lymphocyte Activity,” published in International Journal of Molecular Sciences. We would like to congratulate all the authors, Chaido Sirinian, Anne-Lise de Lastic, Harry Zaverdas, Martha Nifora, Dimitra Georgakopoulou, Martina Samiotaki, Maria Ioanna
- [Successful Completion of the GALATEA Midterm Meeting in Athens](https://insybio.com/successful-completion-of-the-galatea-midterm-meeting-in-athens/) - InSyBio participated in the midterm meeting of the GALATEA Horizon Europe Project, which took place in Athens on 11–12 March 2026 at the Athena Research Center. The meeting marked an important milestone in the implementation of the project and brought together consortium partners from across Europe to review the progress achieved during the first phase
- [InSyBio Selected for the Start4Health ScaleUps Studio Programme](https://insybio.com/insybio-selected-for-the-start4health-scaleups-studio-programme/) - InSyBio has been selected to join the ScaleUps Studio track of the Start4Health programme, an initiative led by Pfizer’s Center for Digital Innovation (CDI). This selection represents an important milestone for the company and further reinforces its position within the digital health innovation ecosystem. Start4Health is designed to connect innovative companies with Pfizer’s innovation ecosystem
- [InSyBio Advances Understanding of Molecular Mechanisms Involved in Human Taste Using Machine-Learning and Network Analytics](https://insybio.com/insybio-advances-understanding-of-molecular-mechanisms-involved-in-human-taste-using-machine-learning-and-network-analytics/) - A unique Machine-Learning and Molecular Modelling pipeline focusing on the interactome of the Taste Receptors has been released in a new publication from the InSyBio team in collaboration with a team of exceptional researchers from Dalle Molle Institute for Artificial Intelligence (Switzerland), and Politecnico di Torino (Italy) in the framework of VIRTUOUS Project, an EU
- [InSyBio Suite Version 3.4 is announced, introducing a major upgrade of the InSyBio Interact tool for advanced protein interaction analysis and biological network discovery](https://insybio.com/insybio-suite-version-3-4-is-announced-introducing-a-major-upgrade-of-the-insybio-interact-tool-for-advanced-protein-interaction-analysis-and-biological-network-discovery/) - InSyBio is thrilled to announce the release of InSyBio Suite Version 3.4, with a major upgrade to the InSyBio Interact tool, an advanced environment for protein analysis, protein–protein interaction (PPI) information retrieval, functional annotation, and biological network creation. InSyBio Interact v3.4 features improved PPI search capabilities supported by a comprehensive database of more than 2
- [New Scientific Publication on Bone Regeneration within the REGENERATION Project](https://insybio.com/new-scientific-publication-on-bone-regeneration-within-the-regeneration-project/) - InSyBio is happy to announce a new scientific publication led by Filip Stojceski, titled “Molecular-level understanding of the aging bone and regeneration mechanisms using computational methods”, published in Osteoporosis International. The article is available as an open-access publication (https://doi.org/10.1007/s00198-026-07903-z )and was developed in the context of the REGENERATION project. The publication provides a comprehensive review
- [InSyBio Accepted into the A4SUSTINNO Accelerator Programme](https://insybio.com/insybio-accepted-into-the-a4sustinno-accelerator-programme/) - InSyBio has been accepted into the A4SUSTINNO accelerator programme, a significant step in the company’s innovation and growth trajectory and an important opportunity to further strengthen its activities in the fields of bioinformatics, artificial intelligence, and digital health. The A4SUSTINNO accelerator is a free acceleration programme addressed to startups and teams active in the digital
- [New Scientific Publication on Biomimetic Bioreactors for Tissue Engineering within the OSTEONET Project](https://insybio.com/new-scientific-publication-on-biomimetic-bioreactors-for-tissue-engineering-within-the-osteonet-project/) - InSyBio is happy to announce a new scientific publication titled “Biomimetic characterization by micro-computed tomography (μCT) of 3D hollow fibre membrane network bioreactors for tissue engineering,” authored by Giuseppe Falvo D'Urso Labate, Chiara Morano, Thomas De Schryver, Harry Zaverdas, Luigi De Napoli, Gionata Fragomeni, Luc Van Hoorebeke, Patrick Segers, Mathieu Boone, Konstantinos Theofilatos, Joerg Christian
- [Position: Full Stack Web Developer ](https://insybio.com/position-1-full-stack-web-developer/) - We are seeking a talented and experienced Full Stack Web Developer to join our team. The ideal candidate will have a strong background in web development, using PHP frameworks (we are using Yii Framework), JavaScript and PostgreSQL. This role involves deploying applications, managing version control through Bitbucket, maintaining WordPress websites and ensuring the smooth operation of all systems. If you
- [Position 1: Junior Software Engineer Developer](https://insybio.com/position-1-junior-software-engineer-developer/) - We are seeking a talented Junior software engineer with a Bachelor's Diploma in Computer Engineering or any related diploma. The hired person will join our interdisciplinary team and work on the development and support of back-end functionalities of our biomedical data analysis platform, InSyBio Suite. Moreover, he/she will be trained to conduct data analysis of
- [Position: Junior Business Development Associate](https://insybio.com/position-2-junior-business-development-associate/) - As a Junior Business Development Associate, the candidate will work closely with customers and their regional sales team to grow and promote the sale of Insybio products and Services. Junior Business Development Associates are the first line of contact with all new customers and along with their regional sales team, they establish and maintain long-term
- [InSyBio announces Novel of Multiple Taste Predictor based on a Multiobjective Machine Learning method](https://insybio.com/insybio-announces-novel-of-multiple-taste-predictor-based-on-a-multiobjective-machine-learning-method/) - A novel predictor for multiple taste sensations based on a multi-objective Machine Learning method was published by InSyBio in the NPJ Science of Food journal of the Springer Nature publishing company (https://rdcu.be/dOVbA). This new predictor, namely Virtuous Multi-Taste, was developed in collaboration with a team of exceptional researchers from Politecnico di Torino (Italy), Industrial Systems
- [InSyBio Harnesses the Power of Clinical Data developing AI tools for Cardiovascular Disease Treatment Optimization](https://insybio.com/syndesis-data-employed-by-insybios-ai-tools-in-cardiovascular-treatment-optimization/) - Cardiovascular diseases (CVDs) are the leading cause of death globally, with 17.9 million annual deaths. InSyBio has partnered with Syndesis, the data and technology catalyst to a truly global, multi-continent network of healthcare and life sciences organizations, to address this enormous global health issue. We focused on two specific heart diseases, congestive heart failure (CHF)
- [InSyBio Suite Version 3.2 is released including an integrated workflow and toolbox for single-cell RNA-sequencing analysis](https://insybio.com/insybio-suite-version-3-2-is-released-including-an-integrated-workflow-and-toolbox-for-single-cell-rna-sequencing-analysis/) - Single-cell RNA sequencing is a powerful genomic method used to detect and analyze RNA molecules in biological samples at a single-cell level. It has proven successful in studying cell composition, proliferation, and migration. However, analyzing the data presents challenges due to standardization issues, data scarcity, and difficulties in integrating datasets with other sequencing technologies. The
- [InSyBio recognized as the best Start-Up Initiative in 2023 at CPHI Pharma Awards](https://insybio.com/insybio-recognized-as-the-best-start-up-initiative-in-2023-at-cphi-pharma-awards/) - Barcelona, October 25th, 2023: CPHI Barcelona announced the winners of the prestigious 2023 CPHI Pharma Awards.
- [Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery](https://insybio.com/syndesis-health-and-insybio-partner-in-predictive-modelling-and-biomarker-discovery/) - Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery.The partnership aims to leverage the clinical and genomic data on Syntium...
- [InSyBio Suite Version 3.1 is released facilitating interactive and efficient network and machine-learning driven multi-omics data analysis](https://insybio.com/insybio-suite-version-3-1-is-released-facilitating-interactive-and-efficient-network-and-machine-learning-driven-multi-omics-data-analysis/) - An increasing number of pharma and academic labs are getting access to multi-omics and multi-modal datasets. However, their processing requires multiple tools, while network analytics and data visualization can become challenging considering the high dimensionality, complexity and the presence of mutual information among different omics technologies. Moreover, predictive analytics using multi-omics data suffers from the
- [Fitly Health & InSyBio have partnered to create the world’s first Metabolic AI™ precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes](https://insybio.com/fitly-health-insybio-have-partnered-to-create-the-worlds-first-metabolic-ai-precision-nutrition-program-for-metabolic-syndrome-prediabetes-and-type-2-diabetes/) - Fitly Health has partnered with InSyBio to deliver life-changing outcomes for patients and employees with metabolic disorders who need to lose weight. Everyone has a unique metabolism and research now shows that our metabolic health is largely affected by diet-influenced changes to our gut microbiome. In other words, existing dietary interventions would be more effective in
- [Understanding Taste by Studying the Protein-Protein Interactions of Taste Receptors](https://insybio.com/understanding-taste-by-studying-the-protein-protein-interactions-of-taste-receptors/) - Understanding the underlined cellular mechanisms of human taste is an essential step for designing new food products and for improving the taste of food, nutraceutical, food supplements and even pharmaceutical products. Moreover, taste mechanisms have been evolutionary linked with protective mechanisms against hazardous compounds, thus understanding how taste works at a molecular level and its
- [Mass Spectrometry Proteomics Data : From raw data to discovery](https://insybio.com/mass-spectrometry-proteomics-data-from-raw-data-to-discovery/) - Introduction to experimental and computational mass spectrometry proteomics pipelines for biomecial application and discovery of biomarkers.
- [InSyBio enters Loyal VC investment Stage 2 and initiates the next financing round](https://insybio.com/insybio-enters-loyal-vc-investment-stage-2-and-initiates-the-next-financing-round/) - In April 2023, InSyBio entered the second investment stage of the Loyal VC program and will receive follow-up funding from the Toronto, Canada-based international fund with active partnerships with Founder Institute and INSEAD. This funding will be part of InSyBio’s ongoing Series A financial round of a total of 2,000,000 Euros, with Loyal VC further assisting in
- [InSyBio wins the Investor Prize in the category of Big Data for Health in Sanofi’s Labs in the VivaTech 2017 event](https://insybio.com/insybio-wins-the-investor-prize-in-the-category-of-big-data-for-health-in-sanofis-labs-in-the-vivatech-2017-event/) - We are proud to announce that InSyBio is the winner of the Investor Prize in the category of Big Data for Health in Sanofi’s “Tech for health” Lab in VivaTech 2017 event (https://vivatechnology.com/) which was held at Paris, 15-17 June, 2017. InSyBio was one of the 34 innovative companies sponsored by Sanofi to join the Viva Technology
- [InSyBio makes the big step to the USA biotechnology market with the help of International Accelerator!](https://insybio.com/insybio-makes-the-big-step-to-the-usa-biotechnology-market-with-the-help-of-international-accelerator/) - InSyBio is the latest startup company to join the International Accelerator program in Austin, Texas USA (https://www.internationalaccelerator.com/) with an ultimate goal to get access to the USA biotechnology market. Labros Digonis, the CEO of InSyBio, who holds a MBA and Master’s Degree in Naval Architecture & Marine Engineering and has over 30 years of experience
- [InSyBio Suite V2.4 has been launched and includes for the first time the InSyBio Biomarkers Tool](https://insybio.com/insybio-suite-v2-4-has-been-launched-and-includes-for-the-first-time-the-insybio-biomarkers-tool/) - The new version of InSyBio Suite has a significant increase in speed and refinement of the predictive biomarkers process. The pioneer InSyBio Biomarkers tool is a unique tool offering single and multi-omics biomarker discovery with a combination of statistical, machine learning and biological network methods. It allows its users to use InSyBio’s patent pending pipeline for biomarker
- [InSyBio reveals novel diagnostic and prognostic biosignature for Glioblastoma and announces its presentation at the 11th annual RECOMB/ISCB Conference on Regulatory & Systems Genomics](https://insybio.com/insybio-reveals-novel-diagnostic-and-prognostic-biosignature-for-glioblastoma-and-announces-its-presentation-at-the-11th-annual-recomb-iscb-conference-on-regulatory-systems-genomics/) - InSyBio’s R&D team applying the company’s proprietary predictive biomarker technology to a collection of data from open omics repositories came up with a novel biosignature of 13 transcripts and a predictive model for glioblastoma diagnosis and treatment. The biosignature not only increases significantly the diagnostic accuracy for glioblastoma but it is able to differentiate it from other types of
- [InSyBio Suite V2.5 has been launched and Includes for the first time a complete pipeline for the analysis of RNA-sequencing data](https://insybio.com/insybio-suite-v2-5-has-been-launched-and-includes-for-the-first-time-a-complete-pipeline-for-the-analysis-of-rna-sequencing-data/) - The new version of InSyBio Suite enables the fast and accurate discovery of transcriptomics predictive biomarkers. The newly introduced pipeline in InSyBio ncRNAseq tool offers efficient, user friendly and secure pre-processing of RNA-sequencing data without having to manually define parameters or select the best algorithm to be used in each step. The interpretation of the revealed
- [InSyBio awarded on Ignite Ideas program organised by Nestle Hellas](https://insybio.com/insybio-awarded-on-ignite-ideas-program-organised-by-nestle-hellas/) - InSyBio has been recently awarded for its superior performance in the context of the Ignite Ideas program (https://igniteideas.gr/en/) which was organised by Nestle Hellas. InSyBio has participated in this program, with its revolutionary idea of personalizing the coffee blend and type selection combining input from a saliva test and responses to questionnaires in order to
- [InSyBio taking steps to help tackle the opioid crisis through precision medicine](https://insybio.com/insybio-taking-steps-to-help-tackle-the-opioid-crisis-through-precision-medicine/) - In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science and the OPERA study (Optimizing Patient Experience and Response to Topical Analgesics) to utilize advanced machine learning methods to not only predict patient response to treatment but also to stratify chronic pain patients into individuals who will
- [Team VIRTUOUS: InSyBio pioneering precision nutrition through European funded project](https://insybio.com/team-virtuous-insybio-pioneering-precision-nutrition-through-european-funded-project/) - In conjunction with a prestigious team of researchers and industry, InSyBio has been awarded funding under the Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) for precision nutrition. Benefiting industry and academia worldwide, the team will work to design an intelligent “virtual tongue” (VIRTUOUS) capable of taste prediction. Through the integration of drug discovery techniques,
- [Novel Stroke biosignature and machine learning model identified for greatest diagnostic accuracy through blood samples](https://insybio.com/novel-stroke-biosignature-and-machine-learning-model-identified-for-greatest-diagnostic-accuracy-through-blood-samples/) - In a close collaboration with a prestigious Austin, TX medical center, InSyBio applied its proprietary technology to identify targeted biomarkers to provide an unbiased, non-interventive diagnostic method for Stroke. This is incredibly important when making clinical decisions in such a time-sensitive situation as stroke, where blood biomarkers could aid in faster diagnosis and treatment. Classifying
- [InSyBio showcasing its breakthrough technology in investment Community of Texas](https://insybio.com/insybio-showcasing-its-breakthrough-technology-in-investment-community-of-texas/) - ISyBio is showcasing as one of 7 prestigious companies during The International Accelerator’s Demo Day taking place October 22nd, 2019 at 4:30pm. As one of the leading companies in targeted biomarker discovery, InSyBio is revolutionizing both the medical and food/nutrition research fields. We drive innovation in both clinical trials and drug discovery through our proprietary analysis
- [JSS forms strategic partnership with InSyBio to pioneer precision medicine innovation in clinical trials](https://insybio.com/jss-forms-strategic-partnership-with-insybio-to-pioneer-precision-medicine-innovation-in-clinical-trials/) - In a bold approach to revolutionize a vital part of the pharmaceutical/nutraceutical industry and change the stagnant norm that is the clinical trial process, JSS Medical Research Inc. has strategically partnered with InSyBio, a leading bioinformatics company, to drive desperately needed transformation. With credit to Axios Investments Corporation for facilitating the partnership, InSyBio and JSS
- [InSyBio Suite V2.6 has been launched offering a unique user experience and allowing exploration of the "dark matter" transcriptomics datasets](https://insybio.com/insybio-suite-v2-6-has-been-launched-offering-a-unique-user-experience-and-allowing-exploration-of-the-dark-matter-transcriptomics-datasets/) - The new version of InSyBio Suite enables the fast and accurate analysis of omics data by non-bioinformatics experts empowered with novel techniques to explore the dark matter of the transcriptomics data. This new version: has a new user interface to optimize the user experience of our subscribers making complex omics and multi-omics data analysis accessible to non-bioinformatics experts allows exploration of previously unmapped reads
- [InSyBio DNA-seq has been launched allowing the discovery of genomic variants and their integration with other omics biomarkers](https://insybio.com/insybio-dna-seq-has-been-launched-allowing-the-discovery-of-genomic-variants-and-their-integration-with-other-omics-biomarkers/) - A new tool has been integrated in InSyBio Suite (InSyBio DNA-seq) which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines. This tool includes the following functionalities: Pre-processing of DNA-sequencing data with optimized pipelines and a user-friendly interface Population analysis of genetics data for the identification of significant genomics biomarkers Integration
- [Precision Chronic Pain Treatment Tool: a first-of-its-kind tool for personalizing treatment of Chronic Pain Patients](https://insybio.com/precision-chronic-pain-treatment-tool-a-first-of-its-kind-tool-for-personalizing-treatment-of-chronic-pain-patients/) - In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science LLC and developed a machine learning-based tool for predicting the response of chronic pain patients to 4 different non-opioid pain treatment formulations. This tool is capitalizing on InSyBio’s unique machine learning technology to develop
- [InSyBio joins Loyal VC program and receives initial investment](https://insybio.com/insybio-joins-loyal-vc-program-and-receives-initial-investment/) - InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors. InSyBio will benefit from active business development support and guidance as well as having
- [Personalizing the treatment of Chronic Pain Patients using the Salonpas® Pain Relieving Patch and Interpretable Artificial Intelligence](https://insybio.com/personalizing-the-treatment-of-chronic-pain-patients-using-the-salonpas-pain-relieving-patch-and-interpretable-artificial-intelligence/) - Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives. In the meantime, the Chronic Pain condition is affecting the lives of millions of patients deteriorating their ability to perform everyday tasks, diminishing their performance in their work environment and, in general, reducing their satisfaction of
- [Optimized and automatized biomarker discovery and processing of biomedical data with InSyBio Pipelines](https://insybio.com/optimized-and-automatized-biomarker-discovery-and-processing-of-biomedical-data-with-insybio-pipelines/) - The new version of InSyBio Suite includes InSyBio Pipelines, a new tool for automatizing and optimizing the computational process for identifying biomarkers. The pioneer InSyBio Pipelines tool allows performing the analysis from raw data until the final biomarkers and predictive models are found in one step simplifying the process and allowing it to be executed by non-machine learning
- [A new tool for processing single cell RNA-sequencing data](https://insybio.com/a-new-tool-for-processing-single-cell-rna-sequencing-data/) - Single-cell RNA-sequencing is a genomic approach for the detection and quantitative analysis of RNA molecules in biological samples and has been extremely successful in the past few years in studying the cell-composition of biological samples, exploring cell proliferation and cell migration mechanisms and providing another layer of information in addition to bulk-RNA sequencing technologies.The new
- [InSyBio facilitates food design through an interpretable Umami taste predictor](https://insybio.com/insybio-facilitates-food-design-through-an-interpretable-umami-taste-predictor/) - InSyBio, through its participation in the Virtuous Project together with a prestigious team of researchers and industry players, has recently contributed to the implementation of the Virtuous Umami tool, a tool which can accurately predict the umami taste. This machine learning-based tool was tested against five databases related to foods or natural compounds and demonstrated

## Pages

- [Welcome](https://insybio.com/) - InSyBio A disruptor to Precision Medicine and Nutrition through biomarker discovery. Read more Try InSyBio Suite for Free InSyBio Diagnostics Identify the best chronic pain non-opioid treatment for you. Read more InSyBio Interact Preprocessing and analysis for proteomics and interactomics biological data. Read more InSyBio ncRNASeq Analysis of non-coding RNA molecules. Read more InSyBio Bionets
- [InSyBio Biomarkers](https://insybio.com/insybio-biomarkers/) - A unique tool offering single and multi-omics biomarker discovery with a combination of statistical, machine learning and biological network methods.
- [InSyBio DNASeq](https://insybio.com/insybio-dnaseq/) - A tool which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines.
- [InSyBio Pipelines](https://insybio.com/insybio-pipelines/) - A tool that takes as input a dataset file and after performing statistical and network analytics, it uses the dataset to train a machine learning model identifying at the same time the optimal biomarkers for the trained model.
- [InSyBio ncRNASeq](https://insybio.com/insybio-ncrnaseq/) - A Non-coding RNA analysis module for predicting and analyzing non-coding RNAs and miRNA target genes.
- [InSyBio Datastore](https://insybio.com/insybio-datastore/) - The evolution of biological research has resulted in numerous experiments which, in turn, have produced a large volume of raw biological data. This effect has created demand for additional storage capacity as well as for for the capability to manage and search through these large biological data sets. InSyBio Datastore supports biology researchers with web-based tools for
- [InSyBio Interact](https://insybio.com/insybio-interact/) - An intracellular interaction analysis module for analyzing proteins and their interactions.
- [InSyBio BioNets](https://insybio.com/insybio-bionets/) - A biological networks analysis module for meta-analysis and visualization of interactive networks, functional characterization of intra-cellular molecules, preprocessing of transcriptomics data and biomarker discovery using a network-based pipeline.
- [Privacy Policy](https://insybio.com/privacy-policy/) - Privacy Policy
- [Solutions for Pharma Industry](https://insybio.com/solutions-for-pharma-industry/) - Preclinical Research: Emphasizing to the cause of a disease Preclinical research, when related to molecular biology data analysis, mostly includes statistical analysis to identify significantly differentiated molecules in the phenotypes under study. This process leads to a high false positive rate and when corrections for multiple testing are performed, most of the time no significant
- [Solutions for Nutrition & Cosmetics Industry](https://insybio.com/solutions-for-nutrition-cosmetics-industry/) - InSyBio’s biomarker discovery technology is able to personalize the application of dietary and nutritional products.
- [Bioinformatics and Software Services](https://insybio.com/bioinformatics-and-software-services/) - Specifically designed for clients that are interested only in the results of some of the InSyBio Suite’s data analysis tools rather than in using the tools.
- [Solutions for Academic Research](https://insybio.com/solutions-for-academic-research/) - Academic research laboratories will benefit from InSyBio solutions, which: Provide all needed bioinformatics products/tools to allow the analysis of multi-omics datasets Facilitate scientific deduction via our biomarker interpretation tools Speed up scientific publication process by integrating biomarker discovery process and providing comprehensive reports for the analysis. See InSyBio Suite in action for academic research workflows:
- [What we are doing at InSyBio?](https://insybio.com/about-insybio/) - Watch the videos or listen to our associates briefly describing InSyBio' s services.
- [InSyBio Team](https://insybio.com/team/) - InSyBio Team
- [Contact Us](https://insybio.com/contact-us/) - USA 750 Boston Neck Road, Suite 11, Narragansett, RI 02882info@insybio.comwww.insybio.com Greece Patras Science Park building Platani, Patras, 26504info@insybio.comwww.insybio.com For more information, please book an introductory meeting with our expert: Dr. Konstantinos Theofilatos, CTO & Technical Sales Manager K.Theofilatos at Calendly
- [InSyBio Personalization Test](https://insybio.com/insybio-personalization-test/) - Our Artificial Intelligence biodata analysis platform, InSyBio Suite, allows building personalized tests in less than a month, minimizing the time and front investment required by at least 80%.
- [Fixed-Price Micro-Analysis Services](https://insybio.com/c-fixed-price-micro-analysis-services/) - All services include: One-hour introductory call with our teams of experts Processing of up to 100 omics samples Analysis report Access to results, figures and documentation for 3 months after the end of the analysis. Custom analysis of omics data is also provided and costing is decided for eachproject separately.Send your request to: sales@insybio.com Schedule
- [Short-Term Access Passes](https://insybio.com/b-short-term-access-passes/) - These licenses can be activated once per client. These costs include: 2 dedicated processing cores 100GB of storage space Credentials for unrestricted access One-hour training webinar Email Support Additional resources can be requested, but will increase the plan’s cost.Send your request to: sales@insybio.com Schedule a free half-hour consultation with our team of experts at:https://calendly.com/k-theofilatos/value-add-call-insybio
- [InSyBio Suite Pricing](https://insybio.com/a-insybio-suite-pricing/) - The costs for these plans are annual costs. These costs include: 4 dedicated processing cores 200GB of storage space Credentials for unrestricted access One-hour training webinar Email Support Unrestricted support calls Additional resources can be requested, but will increase the plan’s cost.Send your request to: sales@insybio.com Schedule a free half-hour consultation with our team of
- [Job Openings](https://insybio.com/job-openings/) - InSyBio Ltd (www.insybio.com) is a rapidly growing and well-funded startupdelivering high quality software products and services in the area of bioinformatics. We are currently expanding our R&D team and are looking for talented people who are excited to work and learn in a quickly growing company. InSyBio wishes to employ two developers with good experience
- [InSyBio White Papers](https://insybio.com/insybio-white-papers/) - If you want to download white papers of InSyBio Suite, you should first subscribe to our Newsletter. Please choose the preferred white paper, fill the form and we will send you an e-mail with the requested white paper. InSyBio BioMarkers Machine learning algorithms, using ensemble and oversampling techniques for Glioblastoma Multiforme Diagnosis SCENARIO: Glioblastoma Download
- [Download RNA-Seq White Paper of InSyBio Suite](https://insybio.com/download-rna-seq-white-paper-of-insybio-suite/) - If you want to download RNA-Seq White Paper, you should first subscribe to our Newsletter. Please fill the following form and we will send you an e-mail with the requested White Paper. If you have already access credentials, go to the login page: Access InSyBio Suite
- [InSyBio Diagnostics](https://insybio.com/insybio-diagnostics/) - This platform provides different Precision Treatment Tools for clinicians and other users. Precision Treatment Tools for Cardiovascular Diseases This is a unique tool that can predict outcomes for specific cardiovascular disease groups and identify the best combination of medications to optimize their outcomes. It has been co-developed and tested using our machine learning technology and
- [Precision Chronic Pain Treatment Tools](https://insybio.com/insybio-chronic-pain-precision-treatment-tools/) - First-of-its-kind tools for personalizing treatment of Chronic Pain Patients.
- [InSyBio @Upatras Osteoarthritis Tool](https://insybio.com/insybio-upatras-osteoarthritis-tool/) - The InSyBio Upatras Osteoarthritis Tool is one of our InSyBio Chronic Pain Precision Treatment tools that are used to stratify chronic pain patients into individuals who will benefit from topical analgesics treatments and select the most suitable non-opioid treatment formulation for them using as input a combination of demographics, clinical characteristics and other responses to
- [InSyBio Chronic Pain Precision Relief @Kailo Tool](https://insybio.com/insybio-chronic-pain-precision-relief-kailo-tool/) - A first-of-its-kind tool for personalizing the treatment of Chronic Pain Patients.
- [InSyBio Chronic Pain Precision Relief @Salonpas Tool](https://insybio.com/insybio-chronic-pain-precision-relief-salonpas-tool/) - A first-of-its-kind tool for personalizing treatment of Chronic Pain Patients.
- [InSyBio Chronic Pain Precision @Topical Analgesics Tool](https://insybio.com/insybio-chronic-pain-precision-topical-analgesics-tool/) - A first-of-its-kind tool for personalizing treatment of Chronic Pain Patients.
- [Precision Treatment Tools for Cardiovascular Diseases](https://insybio.com/precision-treatment-tools-for-cardiovascular-diseases/) - This is a unique tool that can predict outcomes for specific cardiovascular disease groups and identify the best combination of medications to optimize their outcomes. It has been co-developed and tested using our machine learning technology and clinical, demographics, biochemical exams and medications data from Syndesis Health (https://syndesis.com/) database. There are two kind of these
- [Metabolic AI™](https://insybio.com/metabolic-ai/) - Metabolic AI™ tool is being co-developed with Fitly Health and when it is ready we will allow access to it.
- [Machine learning algorithms, using ensemble and oversampling techniques for Glioblastoma Multiforme Diagnosis](https://insybio.com/download-insybio-biomarkers-white-paper-glioblastoma/) - If you want to download InSyBio BioMarkers White Paper, you should first subscribe to our Newsletter. Please fill the following form and we will send you an e-mail with the requested White Paper. If you have already access credentials, go to the login page: Access InSyBio Suite
- [Virtuous Platform](https://insybio.com/virtuous-project/) - Benefiting industry and academia worldwide, the team VIRTUOUS works to design an intelligent “virtual tongue” capable of taste prediction.
- [Thank you!](https://insybio.com/thank-you/) - Thanks for your request! Someone from InSyBio will be in touch with you as soon as possible.
- [Terms Of Use](https://insybio.com/terms-of-use/) - Terms Of Use
- [Scientific Publishing : Simplifying the process with supreme reporting and data sharing mechanisms](https://insybio.com/scientific-publishing-simplifying-the-process-with-supreme-reporting-and-data-sharing-mechanisms/) - Publishing scientific findings in domain-specific journals and announcing them in scientific conferences has become an essential part of today’s research environment. However, supporting these efforts can be a very time-consuming process, and without the proper documentation, the acceptance probabilities can be limited. InSyBio Suite is able to accelerate and significantly ease this pain by providing
- [Scientific Journal Publications](https://insybio.com/scientific-journal-publications/) - #titl
- [Scientific Conference Articles](https://insybio.com/scientific-conference-articles/) - Scientific Conference Articles
- [Quantify then Identify workflow Product/Tool](https://insybio.com/quantify-then-identify-workflow-product-tool/) - A simple version of the product (QtI-Tool) produced from the common project with Nestlé Institute for Health Sciences (NIHS) has been uploaded as an open source project with the copyrights belonging exclusively to InSyBio.
- [Purchase InSyBio Suite](https://insybio.com/purchase-insybio-suite/) - If you want to purchase licenses for the InSyBio Suite's tools, you can request a quote at sales@insybio.com.
- [Purchase InSyBio Precision Chronic Pain Treatment Tool](https://insybio.com/purchase-insybio-precision-chronic-pain-treatment-tool/) - If you want to purchase licenses for the InSyBio Precision Chronic Pain Treatment Tool, you can request a quote at sales@insybio.com.
- [Pay Upon Success BioData Analysis Services](https://insybio.com/pay-upon-success-biodata-analysis-services/) - Expediting your Biodata Analysis & Outcome Prediction Modelling Process - We get it Done
- [Patents](https://insybio.com/patents/) - Theofilatos K, Dimitrakopoulos C, Mavroudi S, Korfiati A, Alexakos C, inventors; InSyBio Ltd, assignee. Protein functional and sub-cellular annotation in a proteome. United States patent application US 15/361,461. 2017 Mar 16. K. Theofilatos et al., Integrated Biomarker Discovery Computational Framework For Nutrition, Cancer And Neurodegenerative Diseases, U.S. Patent Application, 2017
- [MEvA-X Tool](https://insybio.com/meva-x-tool/) - MevA-X is a Hybrid Multi-Objective Evolutionary Tool Using an XGBoost Classifier for Biomarkers Discovery on Biomedical Datasets. The performance of the MEvA-X tool was benchmarked using one omics dataset coming from a microarray gene expression experiment, and one clinical questionnaire-based dataset combined with demographic information. The implementation of MEvA-X tool is available at Github: https://github.com/PanKonstantinos/MEvA-X.
- [InSyBio News](https://insybio.com/company-news/) - News Posted in News New Scientific Publication on TRAF3 in Breast Cancer Cell Survival and Immune Regulation Posted on May 19, 2026May 19, 2026 InSyBio is happy to announce a new scientific publication titled “Dual Role of Cancer Epithelial-Specific TRAF3 in Regulating Breast Cancer Cell Survival and Lymphocyte Activity,” published in International Journal of Molecular
- [InSyBio Mission](https://insybio.com/insybio-mission/) - InSyBio is a global biotechnology company meeting the needs of molecular biology researchers in the academia, private research sector and pharmaceutical companies.
- [InSyBio Cosmetics](https://insybio.com/insybio-cosmetics/) - InSyBio Cosmetics enables users tο identify synthetic and real peptides which demonstrate specific bioactivities
- [InSyBio](https://insybio.com/insybio/) - A disruptor to Precision Medicine and Nutrition through biomarker discovery InSyBio is a privately held Company focusing, through advanced big-data computational tools, on biomarker discovery for Cancer, Neurodegenerative diseases and Nutrition. Biomarker extraction from biological big data (genomics, transcriptomics, proteomics, etc.) is essential for drug discovery & research acceleration, personalized medicine and personalized Nutrition. Modern approaches in
- [Gradually Expanding Dense Neighborhoods (GENA)](https://insybio.com/gradually-expanding-dense-neighborhoods-gena/) - Gradually expanding neighborhoods with adjustment (GENA) is a new algorithm for the computational prediction of protein complexes which makes the realistic assumption that proteins participate in multiple protein complexes and cellular functions. GENA gradually expands neighborhoods in a graph starting from highly informative “seed“nodes. GENA considers proteins as multifunctional molecules allowing them to participate in more than one protein
- [Get a free one month license of InSyBio Suite](https://insybio.com/get-a-free-one-month-license-of-insybio-suite/) - If you want to try InSyBio Suite with your datasets, we offer a full functional trial version. We anticipate that you can use our tools for your research and help us make them better. Please fill the following form and we will contact you short after: If you have already access credentials, go to the
- [Download ncRNASeq White Paper of InSyBio Suite](https://insybio.com/download-ncrnaseq-white-paper-of-insybio-suite-2/) - If you want to download ncRNASeq White Paper, you should first subscribe to our Newsletter. Please fill the following form and we will send you an e-mail with the requested White Paper. If you have already access credentials, go to the login page: Access InSyBio Suite
- [Download BioNets White Paper of InSyBio Suite](https://insybio.com/download-bionets-white-paper-of-insybio-suite/) - If you want to download BioNets White Paper, you should first subscribe to our Newsletter. Please fill the following form and we will send you an e-mail with the requested White Paper. If you have already access credentials, go to the login page: Access InSyBio Suite
- [Diagnostics : Non-invasive high accuracy diagnostics based on biofluids](https://insybio.com/diagnostics-non-invasive-high-accuracy-diagnostics-based-on-biofluids/) - InSyBio’s technology enables the identification of circulating multi-omics markers and bio-signatures in blood and other biofluids
- [Clinical Trials : Targeted patient stratification to speed up the process and reduce the risk of failures in trials](https://insybio.com/clinical-trials-targeted-patient-stratification-to-speed-up-the-process-and-reduce-the-risk-of-failures-in-trials/) - More than 50% of clinical trials currently fail due to low efficacy. InSyBio is able to reduce the risk of failed trials through a two-step process which can be applied in early phase 1 clinical trials. During the first step – discovery – our multi-omics technology can effectively identify markers, signatures and efficacy/toxicity predictive models
- [Webinars](https://insybio.com/webinars/) - [ecs-list-events fromdate="2021-01-01" todate="today" order='DESC']
- [Sample Page](https://insybio.com/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

## Events

- [From Reads to Insights: R for Transcriptomics (Bulk, Single-Cell & Spatial)](https://insybio.com/events/event/from-reads-to-insights-r-for-transcriptomics-bulk-single-cell-spatial-2/) - Overview Jump into R for transcriptomics and turn your bulk, single-cell, and spatial reads into cool insights! From Reads to Insights: R for Transcriptomics Join us online to dive into the world of bulk, single-cell, and spatial transcriptomics using R! Whether you’re curious about analyzing RNA-seq data or visualizing complex expressions, this event’s got you
- [From Reads to Insights: R for Transcriptomics (Bulk, Single-Cell & Spatial)](https://insybio.com/events/event/from-reads-to-insights-r-for-transcriptomics-bulk-single-cell-spatial/) - Overview Jump into R for transcriptomics and turn your bulk, single-cell, and spatial reads into cool insights! From Reads to Insights: R for Transcriptomics Join us online to dive into the world of bulk, single-cell, and spatial transcriptomics using R! Whether you’re curious about analyzing RNA-seq data or visualizing complex expressions, this event’s got you
- [Python for Mass Spectrometry Proteomics & Multi-Omics Analysis](https://insybio.com/events/event/python-for-mass-spectrometry-proteomics-multi-omics-analysis/) - Overview Transform raw mass spectrometry data into biological insights using modern Python workflows for proteomics and integrative omics analysis. From Spectra to Systems: Python for Mass Spectrometry Proteomics & Multi-Omics Analysis Transform raw mass spectrometry data into biological insights using modern Python workflows for proteomics and integrative omics analysis. This hands-on webinar series introduces computational
- [How digital tools can improve your product development](https://insybio.com/events/event/how-digital-tools-can-improve-your-product-development/) - This webinar introduced state-of-the-art digital tools and their application for the different stages of product development. It was co-hosted by EuroPharm , VINC - The Capital of Life Sciences, and InSyBio. It is the 3rd webinar of the series "Increasing pharma SMEs’ competitiveness through digitalization and cooperation with start-ups". The objective of this series is to show
- [Network-Based Analysis for the discovery of diagnostic biomarkers](https://insybio.com/events/event/network-based-analysis-for-the-discovery-of-diagnostic-biomarkers/) - Modern biological network based techniques webinar and demonstration as a tool for the discovery of diagnostic biomarkers. Biological networks have always been a strong tool for bioinformaticians to study the complex underlying mechanisms of diseases. However, their application for the discovery of predictive biomarkers is limited. Biomarker discovery on the other hand is the common
- [Mass Spectrometry Proteomics Data : From raw data to discovery](https://insybio.com/events/event/mass-spectrometry-proteomics-data-from-raw-data-to-discovery/) - Intriduction to experimental and computational mass spectrometry proteomics pipelines for biomecial application and discovery of biomarkers. Mass spectrometry-based proteomics is a strong tool for the proteome of biosamples and has numerous applications for the discovery of diagnostic, prognostic and therapeutic biomarkers. However, there exist several different complementary mass spectrometry based techniques (e.g. labelled vs label
- [Transforming RNA-sequencing Next Generation Sequencing data into knowledge](https://insybio.com/events/event/transforming-rna-sequencing-next-generation-sequencing-data-into-knowledge/) - This event introduced participants to modern bioinformatics, machine learning and AI tools and methods for processing RNA-seq data. Next generation sequencing experiments have allowed among others the identification and the quantification of numerous genes and non coding RNA molecules! Statistical and AI based techniques can inform us about differentially expressed genes and gene signatures which

## Categories

- [News](https://insybio.com/category/news/)
- [Job Openings](https://insybio.com/category/job-openings/)

## Categories

- [Webinars](https://insybio.com/events/category/webinars/)

## Event Tags

- [Transcriptomics](https://insybio.com/events/tag/transcriptomics/)
- [R](https://insybio.com/events/tag/r/)
- [Python](https://insybio.com/events/tag/python/)
- [Mass Spectrometry](https://insybio.com/events/tag/mass-spectrometry/)
- [Proteomics](https://insybio.com/events/tag/proteomics/)
- [Multi-Omics](https://insybio.com/events/tag/multi-omics/)